(Q47713381)

5 February 2018

title

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer (English)

1 reference

5 February 2018

0 references

1 reference

Sartor O

1

1 reference

5 February 2018

Weinberger M

2

1 reference

5 February 2018

Moore A

3

1 reference

5 February 2018

Li A

4

1 reference

5 February 2018

Figg WD

5

1 reference

5 February 2018

language of work or name

English

0 references

publication date

1 August 1998

1 reference

5 February 2018

published in

Urology

1 reference

5 February 2018

volume

52

1 reference

5 February 2018

issue

2

1 reference

5 February 2018

page(s)

252-256

1 reference

5 February 2018

Cortisone treatment in advanced carcinoma of the prostate

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Suramin and prostate cancer: The role of hydrocortisone

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Reduction of Serum Prostate-Specific Antigen during Endocrine or Cytotoxic Treatment of Hormone-Resistant Cancer of the Prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Is prednisolone as good as flutamide in hormone refractory metastatic carcinoma of the prostate?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2898%2900149-6

7 January 2021

10.1016/S0090-4295(98)00149-6

Identifiers

DOI

1 reference

5 February 2018

1 reference

5 February 2018